SpotitEarly

Executive Summary

SpotitEarly is a San Francisco-based diagnostics company developing a non-invasive, at-home breath test for early cancer detection. By analyzing volatile organic compounds (VOCs) in a single breath sample, the test aims to screen for multiple cancer types simultaneously, addressing critical gaps in accessibility, affordability, and convenience. The company’s platform could revolutionize cancer pre-screening by enabling frequent, low-cost testing outside clinical settings. Although still in early development, SpotitEarly targets a large unmet need: improving survival rates through earlier detection. The test's potential to reduce procedural burdens and healthcare costs positions it favorably in the growing liquid biopsy market, though it faces regulatory hurdles and competition from established players like Grail and Exact Sciences.

Upcoming Catalysts (preview)

• Q4 2026First-in-human clinical study results55% success
• Q2 2026FDA Breakthrough Device designation40% success
• Q3 2026Strategic partnership with a major diagnostic lab60% success